Pneumococcal Vaccines Market Trends, Market Research Analysis, and Projections
Pneumococcal Vaccines Market |
Pneumococcal disease is caused by the
bacteria streptococcus pneumonia (also known as pneumococcus). Pneumococcus
infections can occur in the blood, lungs, and brain. Cough, chest pain, fever,
rapid breathing are some of the symptoms of pneumococcal disease. The pneumococcal disease spreads from person to person and causes a variety of health issues.
There are two kinds of pneumococcal vaccines on the market: pneumococcal
conjugate vaccines (PCV13 vaccine) and pneumococcal polysaccharide vaccines
(PPSV23 vaccine). The PCV13 vaccine is approved for use in the immunization of
infants, older adults, and people with certain medical conditions. PPSV23
vaccine, on the other hand, is only approved for people over the age of two. Currently,
the only vaccines available for childhood protection are pneumococcal conjugate
vaccines.
Pneumococcal
vaccines will be more widely used as patient awareness of pneumococcal disease
treatment grows. The rising demand for pneumococcal vaccines as a result of immunization
programmers is also expected to propel the pneumococcal
vaccines market forward. Furthermore, easier access to healthcare
facilities and lower-cost vaccines will provide lucrative opportunities for the
market in the coming years. The increasing number of clinical trials for the
development of pneumococcal vaccines is expected to provide enormous growth and
meet the demand for vaccines for multiple serotypes.
Vaccination
is one of the most cost-effective and risk-free methods of disease prevention.
Pneumococcus is a leading cause of blood infections, pneumonia, sinusitis,
meningitis, and otitis media. It is also the most common infectious disease.
Vaccination,
on the other hand, can help to prevent it. Pneumococcal vaccines are included
in the majority of countries' national immunization programmers for children
under the age of one year. The increased prevalence of pneumococcal diseases
caused by the causative serotype necessitates the development of vaccines with
broader coverage. As a result, there is a growing demand for new pneumococcal
vaccines with broader serotype coverage.
Pfizer,
Inc., Merck & Co. Inc., and GlaxoSmithKline plc. Are among the key players
in the pneumococcal vaccines market.

Comments
Post a Comment